From a therapeutic angle, these observations are of particular importance, because they suggest that, contrary to other diseases such as breast cancer and multiple myeloma where JAM-A inhibitors may represent potential therapeutic strategies [7, 44], JAM-A suppression in CRC may have a detrimental effect on patient outcomes. The gene discussed is F11R; the disease is breast carcinoma.